| Paper reference |
Paper Title |
| FC01.1.1 |
Andrew Walubo
Clinical pharmacology in developing countries: overview of current status and future trends. |
| FC01.1.2 |
Folke Sjöqvist
Promoting clinical pharmacology in developing countries through education and research training |
| FC01.1.3 |
Simon Maxwell
Update of the WHO publication on clinical pharmacology 1970: what we learned from the process and main outcomes |
| FC01.1.4 |
Andrew L Gray
Is WHO's Essential Medicines List contributing to rational medicines use in developing countries? |
| FC01.1.6 |
Meeta Burande
Comparison of efficacy of ORS + Zn verses ORS + Zn + Saccharomyces Boulardii strain in treatment of acute non infective diarrhea in Indian children |
| FC01.4.3 |
Lembit Rägo
WHO Programme for International Drug Monitoring as an effective framework for strengthening national pharmacovigilance systems |
| FC02.1.3 |
Hendrik W van Veen
Molecular pharmacology of the breast cancer resistance protein (ABCG2) |
| FC02.3.4 |
Stefan Broer
SLC6 amino acid transporters |
| FC02.4.2 |
Ingolf Cascorbi
Clinical consequences of transporter variants |
| FC03.1.3 |
Peter A McNaughton
Modulation of TRP channels: impact on pain sensation |
| FC03.1.4 |
Sulayman D Dib-Hajj
Voltage sensitive sodium channels in chronic pain states |
| FC03.2.2 |
Slobodan M Todorovic
Pharmacological regulation of T-type calcium channels in peripheral pain pathways |
| FC04.1.2 |
Olaf H Klungel
Natural experiments in pharmacoepidemiology |
| FC04.1.3 |
Til Stürmer
Treatment decisions and propensity scores |
| FC04.1.4 |
Robert J Glynn
Healthy starters, sick stoppers, and the value of new user designs with active referents in pharmacoepidemiology |
| FC04.2.3 |
Stephen JW Evans
An international perspective on screening for adverse effects of drugs and vaccines – how far can and should active surveillance go? |
| FC04.3.2 |
Stephen JW Evans
Are the available research methods sufficiently valid to address current benefit-risk issues on medicinal products? |
| FC04.3.3 |
Marieke de Bruin
New approaches to fill the methods gap in pharmacovigilance |
| FC04.4.1 |
Trent D Stephens
The impact of thalidomide and its revival as a vital medicine Lessons learned from history |
| FC04.4.2 |
Per Damkier
Pharmacological considerations of drug teratogenicity – why animal studies are not sufficient |
| FC04.4.3 |
Corinne de Vries
Unique methodological features in the pharmacoepidemiology of birth defects |
| FC04.4.4 |
Lolkje TW de Jong-van den Berg
Determining drug effects - Clinical considerations when establishing birth outcomes |
| FC05.2.1 |
Heinrich Taegtmeyer
Insulin resistance: marker or mediator of increased cardiovascular risk? |
| FC05.2.3 |
Steen Dalby Kristensen
Antithrombotic treatment in patients with type 2 DM |
| FC05.3.2 |
Fiona M Gribble
GLP-1 secretion as a prerequisite for the antidiabetic activity of DPP-4 inhibitors: can it be modified? |
| FC06.1.1 |
Michael Sanguinetti
The cardiac hERG channel and arrhythmogenesis |
| FC06.1.2 |
Penelope A Boyden
Would modulating intracellular Ca be antiarrhythmic? |
| FC06.2.2 |
Jean-Marc Davy
Dronedarone for control of ventricular rate during atrial fibrillation: the ERATO study |
| FC06.2.4 |
Eva Delpón
Kv1.5 blockers for atrial fibrillation |
| FC06.3.1 |
Lionel Opie
Metabolic therapy for heart failure |
| FC06.3.2 |
Juan Tamargo
New therapeutic targets in heart failure |
| FC06.4.4 |
Mark E Anderson
Rescuing a failing heart |
| FC07.2.1 |
Amin Rostami-Hodjegan
Can we predict pharmacokinetics (PK) in disease populations? |
| FC07.2.2 |
Mats O Karlsson
Integrated models for the glucose – insulin system |
| FC07.2.3 |
Blanca Rodriguez
Heart modelling in drug development |
| FC07.3.2 |
Marc Pfister
Modeling and simulation in clinical drug development at Bristol-Myers Squibb |
| FC07.4.3 |
Yuki Ando
Role of modelling and simulation for drug approval in Asia |
| FC07.4.4 |
Siv Jönsson
Exposure-response and disease modelling from a regulatory view |
| FC08.1.1 |
Delphine Behr-Roussel
Animal models for sexual dysfunction and cardiovascular disease |
| FC08.1.3 |
Javier Angulo
Treatment of sexual dysfunction associated with cardiovascular disease |
| FC08.1.4 |
Graham Jackson
Effects of cardiovascular drugs on sexual function |
| FC08.1.5 |
Jackie D Corbin
Phosphodiesterase type 5 and inhibitors – an update |
| FC08.3.2 |
Christopher H Fry
Modulation of electromechanical coupling in the bladder |
| FC09.1.2 |
Christian Taube
The mast cell as a target for anti-asthma drugs |
| FC09.2.1 |
Marc Feldmann
TNF-α antagonists – translating molecular insights in autoimmunity into effective therapy |
| FC09.2.3 |
Michael G Tovey
Immunogenicity and other problems in the use of biologicals |
| FC09.2.4 |
Niels Graudal
Similar effects of disease modifying anti rheumatic drugs, glucocorticoids and biologics on radiographic progression in rheumatoid arthritis. Meta-analysis of 70 randomised placebo or drug controlled studies including 112 comparisons |
| FC09.4.2 |
Paola Patrignani
Anti-inflammatory benefits and cardiovascular toxicity of NSAIDs and COX-2 inhibitors |
| FC09.4.6 |
Vincenzo Brancaleone
The role of formyl peptide receptor 2 (Fpr2) in leukocytes trafficking |
| FC09.5.1 |
Guy G Bruselle
Dendritic cells as targets for immunomodulation in asthma and COPD |
| FC09.5.7 |
Adam Al-Kashi
Calcitonin and glucocorticoids - a novel approach to anti-inflammatory co-therapy |
| FC10.1.1 |
Gérard Pons
Place of the innovative methodological approaches in the development of medicinal products in children |
| FC10.1.2 |
Emilio J Sanz
Increasing role of the observational approaches in the assessment of safety and efficacy of medicinal products in children |
| FC10.1.3 |
Karen I Barnes
A collaborative approach to improving the treatment of malaria: the Worldwide Antimalarial Resistance Network |
| FC10.2.3 |
Shalini Sri Ranganathan
Essential medicines list for children, what it means for the developing countries |
| FC10.2.4 |
Gregory L Kearns
Case: use of old data and modern scientific methods to provide more rational dosing and FDC formulations of TB medicines for children |
| FC10.3.1 |
Atieno Ojoo
End-user specifications for optimal paediatric formulations |
| FC10.3.2 |
Jörg Breitkreutz
Novel drug formulations for children |
| FC10.3.3 |
Anthony J Nunn
Adapting formulations for children |
| FC10.4.2 |
John N van den Anker
Developmental pharmacology of immature organs |
| FC10.4.3 |
Karel Allegaert
Neonatal analgesia: still in search of a balanced approach? |
| FC10.5.4 |
Shumpei Yokota
Use of biopharmaceuticals in pediatric field: Tocilizumab, an anti-IL-6 receptor monoclonal antibody, for children with systemic juvenile idiopathic arthritis |
| FC11.5.1 |
Bräuner-Osborne
Characterization of GPRC6A – a promiscuous 7TM receptor activated by basic L-amino acids |
| FC11.5.2 |
P Jeffrey Conn
Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders |
| FC12.1.2 |
William Catterall
Mechanisms of hyperexcitability and co-morbidities in severe myoclonic epilepsy of infancy |
| FC12.2.1 |
Sulayman D Dib-Hajj
Functional effects of sodium channel mutations in inherited chronic pain syndromes |
| FC12.3.2 |
Alfred L George
Sodium channelopathies in cardiac arrhythmia |
| FC12.3.4 |
Bernard C Rossier
Liddle’s disease and salt-dependent hypertension |
| FC12.4.4 |
Louis J Ptacek
Channels in muscle disease |
| FC13.1.1 |
Kees van Grotheest
Adverse drug reactions in hospitals |
| FC13.1.2 |
Michael A Ibara
An industry perspective of drug safety |
| FC13.1.3 |
Alasdair Breckenridge
Drug regulation and drug safety |
| FC13.1.4 |
Simon Thomas
Clinical toxicology perspective of drug safety |
| FC13.4.1 |
David B Goldstein
Safety pharmacogenomics |
| FC13.5.3 |
Jörn Lötsch
Genetic variability of pain perception and treatment |
| FC14.1.1 |
Sharon Walsh
Efficacy of current pharmacotherapies for opioid dependence: What challenges remain? |
| FC14.2.2 |
Giovanni Addolorato
Targeting GABA system: role of GABABergic drugs |
| FC14.3.2 |
Yavin Shaham
The role of the drug environment in relapse to drug seeking: lessons from rat studies |
| FC14.3.4 |
Harriet de Wit
Incubation of craving in cigarette smokers |
| FC14.4.2 |
Markus Heilig
Stress related neuropeptides: Candidate treatment targets in alcoholism |
| FC14.4.4 |
Charles Chavkin
The role of kappa-opioid transmission in dysphoric states related to stress and addiction |
| FC14.5.1 |
Harrison G Pope
Societal aspects of doping |
| FC14.5.3 |
Ruth I Wood
Anabolic-androgenic steroid addiction? Insights from animal |
| FC15.3.2 |
Yu Huang
COX-2 products |
| FC15.3.4 |
William B Campbell
Endothelial 15-lipoxygenase eicosanoids |
| FC15.4.2 |
Csaba Szabó
Gaseous signalling molecules: the biological effects of hydrogen sulfide - comparison with nitric oxide |
| FC16.1.1 |
Valerie Schini-Kerth
Red wine polyphenols |
| FC16.1.2 |
Thomas F Lüscher
Cardioprotection by natural products: dark chocolate |
| FC16.2.1 |
Zhi-Bin Lin
Pharmacological and clinical research on Ganoderma lucidum (Lingzhi) in China |
| FC16.3.3 |
Kinzo Matsumoto
Choto-san and recognition behaviour |
| FC16.4.2 |
Arunabha Ray
Philosophy of Ayurvedic medicine and beyond |
| FC16.4.3 |
Arnold G Herman
Contributions of plant-derived products to Western medicine |
| FC16.5.2 |
Monique Simmonds
Authentication of natural products |
| FC16.5.4 |
Josephine P Briggs
Challenges in research on natural products and dietary supplements |
| FC17.1.2 |
Albert Gjedde
Cortical and subcortical dopamine receptor interactions in sensation-seeking |
| FC17.2.3 |
P Jeffrey Conn
Allosteric modulators of GPCRs for treatment of schizophrenia |
| FC17.3.1 |
Shitij Kapur
The speed and onset of antipsychotic response - implications for theory and practise |
| FC17.3.3 |
Andreas Meyer-Lindenberg
Personalized procognitive pharmacotherapy in schizophrenia |
| FC17.3.4 |
Verity J Brown
Prospectives for treatment of with cognitive enhancers or treatment of cognitive impairment |
| FC17.4.4 |
David J Nutt
Understanding Current Antidepressants’ Action as a Way to Develop Improved Therapies |
| FC17.5.1 |
Elisabeth B Binder
Using gene x environment interactions to target personalised treatment in mood disorder. |
| FC17.5.3 |
Eric Vermetten
Can brain mechanism in PTSD help direct treatment advances? |
| FC18.2.1 |
Christopher K Glass
Nuclear receptor-dependent repression mechanisms that regulate inflammation |
| FC18.2.3 |
Peter J Fuller
Mineralocorticoid receptor and vascular function |
| FC18.3.4 |
Gary E Landreth
Liver X receptors as therapeutic targets in Alzheimer's Disease |
| FC18.4.3 |
Shigeaki Kato
The role of co-regulators/co-regulator complexes in NR function |
| IUL |
Paul M Vanhoutte
The 50-Years IUPHAR Anniversary Lecture: regenerate to be old |
| PL01 |
Salvador Moncada
Vascular endothelium: physiology, pharmacology and vascular disease |
| PL13 |
Jes Olesen
New drug targets for headache |
| PL15 |
Sue P Duckles
Understanding the neuroprotective effect of estrogen; inflammation, age and mitochondria |
| PL16 |
Olavi Pelkonen
Drug metabolism - past, present and future |
| PL17 |
Morris J Brown
Therapeutic potential of vaccines in the management of hypertension |
| PL18 |
Ian E Hughes
Teaching pharmacology in 2020 |
| PL20 |
Ernesto Schiffrin
Renin-angiotensin system and vascular inflammation |
| PL21 |
Thomas Lönngren
Successes and challenges in drug development - a regulatory perspective |
| PL23 |
Elisabeth Bock
New molecular targets in Alzheimer’s disease |
| SS01.1 |
Michael Davidson
Risk/benefit assessment of antipsychotic drugs in clinical practice |
| W01.2.2 |
John Ian McGrath
Localisation of adrenoceptors in live native tissue |
| W01.3.1 |
Salomon Z Langer
Possible therapeutic uses of release-modifying drugs acting on autoreceptors and neuronal transporters |
| W02.1.1 |
Gary K Beauchamp
Development of taste perception and food preference in human infants |
| W02.1.2 |
Vasiliy Zolotarev
Dietary glutamate signal evokes gastric juice excretion in dogs |
| W02.2.2 |
Sandor Szabo
The changing organ/disease targets & new molecular mechanisms in GI pharmacology |
| W02.2.4 |
Prostaglandin EP receptors and their roles in mucosal protection and ulcer healing in gastrointestinal tract |
| W03.1 |
Marcello Trevisani
TRPV1 antagonists for pain relief, cough, and incontinence |
| W04.1.5 |
Ramaronson Andriantsitohaina
Different facets of microparticles in the metabolic syndrome |
| W04.2.1 |
Ernesto Schiffrin
Anti-oxidants and cardiovascular health |
| W04.2.3 |
Valerie Schini-Kerth
Anti-oxidant potential of polyphenols |
| W04.2.4 |
Andreas Daiber
Future strategies for therapeutic use of antioxidants |
| W04.3.2 |
Urs T Ruegg
Investigations of green tea polyphenols using the mouse model of Duchenne Muscular Dystrophy |
| W04.3.3 |
Huige Li
Sirtuin1 is a molecular switch for cardiovascular oxidative stress |
| W04.3.4 |
Christopher Rembold
Success and failures in the use of anti-oxidants |
| W05.1 |
Hakki Zafer Güney
Pharmacovigilance and the role of pharmacologists - what else can be done? |
| W05.4 |
Carl-Olav Stiller
The role of clinical pharmacologists in expertorganizations recommending drugs for the greater Stockholm area |
| W06.2 |
Micheline Piquette-Miller
Inflammation-mediated alterations on drug transporters; implications on therapeutic drug response |
| W06.4 |
Vincent Pichette
Evidence of the impact of kidney disease on drug metabolism and transport |
| W06.5 |
Patrick du Souich
Clinical and therapeutic repercussions of disease-induced down-regulation of the cytochrome P450 and of membrane transporters |
| W07.4 |
Jean Clairambault
Mathematical modelling of cell proliferation, circadian rhythm and pharmacokinetics-pharmacodynamics to optimise cancer treatments |
| W08.2 |
Ramaronson Andriantsitahoina
Different facets of microparticles in the metabolic syndrome |
| W08.4 |
Monica Montagnani
Vascular actions of insulin |
| W09.1 |
Maria José Alcaraz
Cytokines and inflammatory disease |
| W09.3 |
Santiago Redondo
Cell response of TGF-beta takes central stage in therapeutical design |
| W09.5 |
Francisco Fernandez-Aviles
Stem cell therapy for cardiac repair. Facts and hopes from a clinical point of view |
| W10.1 |
Michael Hardman
EMTRAIN - European Medicines Research Training Network |
| W10.2 |
Theodor Guentert
SafeSciMET - European modular education and training programme in Safety Sciences for Medicine |
| W10.3 |
Fritz Bühler
PharmaTrain – pharmaceutical medicines training programme |
| W11.3 |
Aletta D Kraneveld
Gut-brain and brain-gut axis revisited: possible implications in IBD and food allergy |
| W12.1 |
Asbjørn Mohr Drewes
Experimental pain and analgesics - introduction |
| W12.2 |
Lars Arendt-Nielsen
Translational human pain biomarkers in drug development |
| W12.4 |
Marieke Niesters
Ketamine: Acute and chronic pain relief and its influence on diffuse noxious inhibitory control |
| W12.5 |
Trine Andresen
Tissue differentiated effects of transdermal buprenorphine and fentanyl |
| W12.6 |
Christina Brock
Experimental pain: the role of descending inhibition and implications for drug research |
| W13.4 |
Heinz H Pertz
The role of α2C-adrenoceptors in UK14304-induced vasoconstrictor responses in rat tail arteries: potential relevance in Raynaud’s phenomenon |
| W14.2 |
Roger J Summers
Relaxin family peptides and their receptors: realising the therapeutic potential |
| W15.1 |
David B Bylund
Integrative and organ systems pharmacology |
| W15.3 |
Christian B Brink
IOSP in Africa |
| W16.2 |
Guilherme Suarez-Kurtz
Challenges of global implementation of pharmacogenetics into clinical practice |
| W16.4 |
Andrew Somogyi
Obstacles to the implementation of pharmacogenetic testing in Australia |
| W16.6 |
Vural Özdemir
Postgenomics medicine, empiricism and ethics of bioethics: preventing both underprotection of subjects and misdirected precaution |
| W17.1 |
Michael J Mulvany
ORPHEUS: towards standards for PHd education in biomedicine and health sciences in Europe |
| W17.2 |
Nicolas Goulding
Working towards PhD standardization in the UK |
| W17.3 |
Joey W Barnett
Standards for Ph.D. Education in the United States |
| W17.4 |
Hans Orer
Setting the standards for PhD education in Turkey, keeping up with dynamisim, giving up the nonesense |
| W18.3 |
Paola Patrignani
Insights into the efficacy and risk management of COX-2 inhibitors: an example of translational medicine |
| W20.1 |
Paul White
e-learning and e-assessment in pharmacology |
| W20.2 |
Christian B Brink
Teaching pharmacology in a global arena |
| W20.3 |
Patangi K Rangachari
Active teachers/ engaged students: a status report |
| W20.4 |
Simon Maxwell
Pharmacology education for clinical students |
| W21.2 |
Jaana Rysä
Novel immunomodulatory factors in cardiac hypertrophy and heart failure |
| W21.3 |
Katja Puttonen
Neuroinflammation - Stem-cell derived neural progenitors and inflammatory response in a mouse model of cerebral stroke |
| W21.4 |
Suvi Ruohonen
Inflammation and obesity - Neuropeptide Y in pathogenesis of metabolic syndrome |
| W23.1 |
Hiroshi Watanabe
PGx from research into clinical practice (overview) |
| W24.1 |
Michel Goldman
Innovative Medicines Initiative: The EU at the forefront of novel R&D partnerships |
| W24.2 |
Christian R Noe
Challenges and opportunities in drug research |
| W26.1 |
Lars Arendt-Nielsen
Translational human pain bio-markers in early drug development |
| W27.4 |
Alexander Dodoo
Clinical testing and pharmacovigilance data for scientific evaluation of medicinal plants used in traditional medicine |
| W29.2 |
Inga Odenholdt
Prediction of individual antibiotic dose in the clinic |
| W30.3 |
Valerie Schini-Kerth
Posttranslational regulation of eNOS activity |
| W30.4 |
Huege Li
Multiple ways to target eNOS: killing N birds with one stone |
| W31.1 |
Timothy NC Wells
New medicines to improve control and contribute to the eradication of malaria |
| W31.3 |
Joao Santana da Silva
New perspectives to treat Trypanosome infection using NO donors |
| W31.4 |
Mauro M Teixeira
Anti-inflammatory strategies to treat severe infections |
| W32.1 |
Pia Caduff-Janosa
The H1N1 story: the black and the white |
| W32.2 |
Nicholas Moore
From signals to therapy |
| W32.3 |
Brian Edwards
New safety approaches towards advanced therapies |
| W32.4 |
Alex Dodoo
Between the rock and a hard place – safety monitoring of medicines for neglected diseases |
| W33.1 |
Athineos Philippu
Approaches to synaptic events in vivo under physiological and pathological conditions: state of the art |
| W33.4 |
Christina Dalla
Sex differences in animal models of depression: focus on behavioural and neurochemical manifestation |
| W34.1 |
Zoran Todorovic
Bioethical principles in pharmacology: teaching of animal bioethics at the School of Medicine, University of Belgrade |
| W34.3 |
Violeta Stanimirovic
Importance of pharmaco-toxicological evaluation of increased drug impurities and preserving drug quality and patient's safety |
| W34.5 |
Viktorija Dragojevic-Simic
Ethical committees of healthcare institutions in Serbia: Who guards patient safety? |
| W35.1 |
Petra A Thürmann
From pharmacovigilance to patient safety: prevention of adverse drug events |
| |
